Italy Fines Apple €98.6 Million Over App Store Dominance 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
PHOENIX, Dec. 08, 2016 -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today issued the following statement regarding the Department of Justice / U.S. Attorney’s Office / District of Massachusetts press release:
The charges against individuals discussed in the DOJ press release relate to previously disclosed investigations. Insys continues to cooperate with all relevant authorities in its ongoing investigations and is committed to complying with laws and regulations that govern our products and business practices. Insys will not provide additional information or comments at this time on this matter.
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients.
Investor Contact: Lisa M. Wilson Email: [email protected]
